Teva Branded Pharmaceutical Products R&D LLC. et al. v. Amneal Pharmaceuticals of New York, LLC et al.

Docket No.
24-1936
Appellate Court
Federal Circuit

Goal

  • Block infringement of a patent

Litigation Content

Why this Matters:

The plaintiffs argue that defendants infringed several of their patents, and defendants counter that plaintiffs improperly listed certain patents in the Orange Book to maintain exclusivity and block other generics from entering the market in violation of federal patent and antitrust law. Patent abuses can distort the market for prescription drugs and drive up prices for consumers.

Potential Impact:

Improper patent listings in the Orange Book can undermine fair competition and prohibit or delay consumers from accessing lower-cost generic drugs.

51 Major Filings

View More

Litigation Information

Current Status

Decision issued